DENVER, Oct. 31 /PRNewswire/ -- Myogen, Inc., a Colorado-based
biopharmaceutical company dedicated to discovering, developing and
commercializing drugs for the treatment of cardiovascular diseases, announced
today the appointment of Jerry T. Jackson, former Merck & Co. executive, to
its Board of Directors. Mr. Jackson has more than thirty-five years of
executive experience in the pharmaceutical industry.
"Jerry brings to our Board of Directors a rich and diverse set of
leadership experiences from one of the most successful and innovative
companies in the pharmaceutical industry," commented Dr. J. William Freytag,
President and Chief Executive Officer of Myogen. "His broad knowledge base
and experience with success will prove valuable for guiding our development as
a corporation."
"I am very pleased to join Myogen at such a critical and exciting stage in
its development," said Mr. Jackson. "Myogen's two late-stage product
candidates and its expertise in the molecular bases of cardiovascular disease
position the company to be a leader in the treatment of cardiovascular
disease, the leading cause of death and disability in the United States."
Mr. Jackson was employed by Merck & Co., Inc., a major pharmaceutical
company, from 1965 until his retirement in 1995. From 1993 until retirement,
Mr. Jackson served as Executive Vice President of Merck with broad
responsibilities for numerous operating groups -- including being President of
Merck's Worldwide Human Health Division in 1993 and Senior Vice President
responsible for Merck's Specialty Chemicals Business in 1991-1992.
Previously, he was President of Merck's International Division. Mr. Jackson
has served on the board of directors of several biotech pharmaceutical
companies and currently is on the board of Alexion Pharmaceuticals, Inc.,
Intrabiotics Pharmaceuticals, Inc. and M D Edge, Inc.
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of therapeutic drugs for the treatment of
cardiovascular diseases. Cardiovascular diseases are the leading cause of
death and disability in the United States, claiming more than one million
lives annually and having associated healthcare costs of approximately
$200 billion per year. The Company's academic founders, collaborators and
staff have been working for more than 20 years to define the molecular bases
of cardiovascular disease and to optimize its treatment. The Company believes
that its expertise provides it with the capability to discover, develop and
optimize therapies that address the underlying mechanisms of cardiovascular
disease, evaluate and in-license product candidates and guide clinical
development efforts. Myogen currently markets one product in Europe for the
acute treatment of advanced heart failure, and it has two product candidates
in late-stage clinical development for three cardiovascular indications. In
addition, the Company has developed a portfolio of molecular therapeutic
targets that it believes play key roles in heart disease. Myogen occupies
22,000 square feet of laboratory and office space in the Denver, Colorado area
and currently has approximately 45 employees. Please visit our website at
http://www.myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
J. William Freytag, Ph.D., President & CEO,
+1-303-464-5221, or Joseph L. Turner, Chief Financial Officer,
+1-303-464-5222, joe.turner@myogen.com , both of Myogen, Inc.
|
